A subscription to JoVE is required to view this content. Sign in or start your free trial.
This protocol provides a detailed description of sorting extracellular vesicles (EVs) released by mesenchymal stromal cells. In particular, it focuses on the instrument setting and the optimization of the sorting conditions. The goal is to sort extracellular vesicles while preserving their characteristics.
Extracellular vesicles (EVs) released by mesenchymal stromal cells (MSCs) contain a set of microRNAs with regenerative and anti-inflammatory roles. Therefore, purified MSC-EVs are envisioned as a next-generation therapeutic option for a wide array of diseases. In this protocol, we report the strategy for successfully sorting EVs from the supernatant of adipose-derived MSCs (ASCs), often used in orthopedics regenerative medicine applications.
First, we described the sample preparation, focusing on EV isolation and labeling steps with carboxyfluorescein succinimidyl ester (CFSE) for fluorescence detection; subsequently, we detailed the sorting process, which constitutes the main part of the protocol.
In addition to the rules defined by MISEV 2023 and MIFlowCyt EV guidelines, we applied specific experimental conditions concerning nozzle size, frequency, and sheath pressure. Morphological parameters are established using beads of diameters selected to cover the theoretical range of EV size. After ASC-EVs sorting, we performed a purity check of the sorted fraction by re-analyzing it with the sorter and verifying the EV size distribution with the nanoparticle tracking analysis technique.
Due to the increasing importance of EVs, having a pure population to study and characterize is becoming crucial. Here, we demonstrate a winner strategy to set up sorting to achieve this goal.
Extracellular Vesicles (EVs) are a heterogeneous group of membrane-structured vesicles released by almost all cells, delimited by a lipid bilayer, unable to replicate on their own1. They can be found in several biofluids such as blood plasma, serum, saliva, breast milk, urine, bronchial lavage fluid, amniotic fluid, cerebrospinal fluid, and malignant ascites2. One of the main functions of EVs is to transport various molecules, including nucleic acids, proteins, lipids, and carbohydrates, between a donor and a recipient cell. This can occur through various mechanisms, such as direct membrane fusion, receptor-ligand interaction, endocytosis, and phagocytosis3,4. For this reason, they have been demonstrated to play an important role in a lot of physiological and pathological processes, and they show considerable promise as novel biomarkers of disease, as drug delivery vehicles, and as therapeutic agents5,6.
Mesenchymal stromal cells (MSCs) are multipotent cells that can be isolated from many tissues, including adipose tissue, dental pulp, umbilical cord blood, placenta, amniotic fluid, Wharton's jelly, and even the brain, lung, thymus, pancreas, spleen, liver, and kidney. In recent years, they have attracted considerable interest in regenerative medicine7. Adipose-derived mesenchymal stem cells (ASCs) can be harvested from fat tissue through a less invasive procedure compared to other sources like bone marrow, resulting in lower risks of severe complications and avoiding ethical issues8.
Additionally, adipose tissue contains a significantly higher concentration of MSCs than bone marrow (1% versus >0.01%) and other sources such as the dermis, dental pulp, umbilical cord, and placenta. MSCs are crucial in the regeneration of injured tissues and cells due to their differentiation ability and their secretion of a broad repertoire of growth factors, chemokines, and cytokines; these therapeutic benefits are attributable to their differentiation ability but also to the fact that they secrete a broad repertoire of growth factors, chemokines, and cytokines. A striking example is given by MSCs' therapeutic potential for orthopedic conditions, with the term "Musculoskeletal Diseases" having the higher number of registered clinical studies under clinicaltrials.gov (accessed 13th May 2024).
Moreover, MSCs can also secrete EVs that take part in tissue regeneration via transferring information to damaged cells or tissue and exert biological activity similar to the mother cells9,10. For this reason, MSC-EVs may be a valuable substitute for cell therapy to achieve a cell-free approach11, with two clinical studies involving MSC-EVs for orthopedic conditions (NCT05261360 and NCT04998058). However, several challenges still exist for the clinical applications of EVs. For example, there are some concerns about EV isolation techniques: most of them do not guarantee vesicle purity or integrity. Moreover, some isolation techniques are complex, time-consuming, and have low repeatability, making them unsuitable for clinical use12.
Cell sorting, on the other hand, is a commonly used method that allows for the isolation of single cells from heterogeneous cell suspensions by using specific fluorescent markers13. It can be used for many applications and adapted to different sample types. However, although cell sorting is a well-established and widely used technology, EV sorting is still very challenging because most EVs are below the minimum detection threshold for even the most sensitive flow cytometers. There are some features that make a sorter more suitable for this purpose. First of all, using a Jet-in-air system in which the stream suspending the particles is interrogated by lasers in air, rather than within a flow cell; this system preserves the sample by decreasing the stress to which it is subjected. A second important point is the presence of an "obscuration" bar between the stream and the collection lens that decrease the background optical noise of the instrument. Although it is low, the background noise is not completely eliminated and constitutes a reference that provides a partial window into the events that fall under the threshold: it is very important for the analysis of events that are close to the "limit of detection" of the instrument14. Finally, the sorter features a dual-path Forward Scatter (FSC) with two different masks that allow for improved discrimination between small and large particles in the sample.
Based on this, we developed a protocol aimed to separate carboxyfluorescein succinimidyl ester (CFSE) labeled MSC-EVs by using a high-sensitivity cell sorter. To minimize the manipulation of EVs and preserve their integrity and quantity, we avoided ultracentrifugation steps during the sample preparation. Furthermore, sorting conditions were adjusted to minimize stress on the vesicles, including further optimization of our instrument by reducing the sorting pressure associated with the nozzle size (70 μm nozzle for a pressure of 35 psi).
The protocol here consists of four parts: (1) Sample preparation, (2) ASC-EVs characterization, (3) ASC-EVs sorting, and (4) Post sorting analysis. A schematic representing the workflow is shown in Figure 1.
Figure 1: Protocol Flow chart. The flow chart shows the steps involved in the protocol. (1) sample preparation, (2) characterization of vesicles before sorting, (3) sorting, and (4) analysis of vesicles post-sorting. Please click here to view a larger version of this figure.
1. Sample preparation
2. ASC-EVs characterization
Figure 2: ASC-EVs characterization. (A) Representative Western blot of EVs positive (CD9, CD81, TSG101, and Flotillin) and negative (Calnexin) markers. Corresponding molecular weights are reported, and ASCs lysates have been used as control. (B) Flow cytometry analysis of EVs markers. The expression of the following markers was analyzed: CD9, CD63, CD81 and CD44. Only CFSE-positive ASC-EVs were analyzed for marker expression. Histograms represent unstained (red histograms) and stained (blue histograms) ASC-EVs.(C) Flow cytometry intracellular analysis of EVs marker Caveolin. Histograms represent unstained (grey histogram) and stained (blue histograms) ASC-EVs.(D) Characterization of ASC-EVs by NTA. Histograms represent the concentration (particles/mL)/size (nm) of the sample. (E) Visualization of ASC-EVs by TEM. Scale bars = 100 nm. Please click here to view a larger version of this figure.
3. ASC-EVs sorting
Figure 3: Physical parameter setting with hollow organo silica beads. (A) SSC/FITC dot plot: reference green, fluorescent beads have been used to set SSC parameter. SSC/FSC dot plot of (B) VER01B and (C) VER01A beads. Please click here to view a larger version of this figure.
Figure 4: Reference background noise. (A) SSC/CFSE dot plot of PBS sample. (B) SSC/CFSE dot plot of PBS + CFSE sample. Please click here to view a larger version of this figure.
Figure 5: CFSE stained ASC-EVs sorting. (A) SSC/CFSE dot plot of unstained EVs, (B) CFSE stained EVs, (C) CFSE negative EVs post-sorting, and (D) CFSE positive EVs post-sorting. Please click here to view a larger version of this figure.
4. Post sorting analyses
NOTE: Due to the limited amount of material after sorting, it may not be possible to perform all analyses. With the amount obtained, the following are performed.
Figure 6: Characterization of sorted ASC-EVs. Flow cytometry analysis of EV markers. The expression of the following markers was analyzed: CD9, CD63, CD81, and CD44. Only CFSE-positive ASC-EVs were analyzed for marker expression. (A) Histograms represent unstained (red histograms) and stained (blue histograms) ASC-EVs. (B) Characterization of ASC-EVs by NTA. Histograms represent the concentration (particles/mL)/size (nm) of the pre-sorting (left) and post-sorting (right) samples. (C) Visualization of ASC-EVs by TEM of pre-sorting (left) and post-sorting (right) sample. Scale bars = 100 nm. Please click here to view a larger version of this figure.
The FSC polystyrene beads have been sorted to validate the instrument setup and sorting conditions. FSC polystyrene beads are a mix of fluorescent beads ranging from 100 nm, 300 nm, 500 nm, and 900 nm and are visible on the FITC channel. Figure 7A shows the SSC log scale versus the FITC log scale dot plot with the four populations of beads before sorting. The fluorescent populations of 100 nm, 300 nm, and 500 nm were gated and sorted. Sorted beads were analyzed for purity and enrichment as a...
Analyzing and sorting EVs is challenging due to their small size and the fact that they are near the detection limit of most flow cytometers. Our objective was to develop a protocol for isolating EVs derived from AMSCs labeled with CFSE. CFSE was selected as the staining method due to its reported high EVs labeling efficiency (≥90%), without the formation of unwanted particles such as protein aggregates given by antibodies. Nevertheless, it is possible that few EVs without esterase could be missed and future studie...
The authors have nothing to disclose.
We thank Emanuele Canonico for technical support. Part of this work was carried out in ALEMBIC, an advanced microscopy laboratory established by IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele. The work of Enrico Ragni and Laura de Girolamo was supported by the Italian Ministry of Health, "Ricerca Corrente".
Name | Company | Catalog Number | Comments |
5(6)-Carboxyfluorescein diacetate N-succinimidyl ester | Merck | 150347-59-4 | |
Adipose Mesenchymal Stromal Cells | Wepredic, Parc d'affaires, 35760 Saint-Grégoire, France | Cells used in this study | |
Alexa 488 anti-Caveolin | R&D Systems | IC5736G | Flow cytometry antibody |
APC anti-human CD44 | BioLegend | 338805 | Flow cytometry antibody |
APC anti-human CD63 | BioLegend | 353007 | Flow cytometry antibody |
APC anti-human CD81 (TAPA-1) | BioLegend | 349509 | Flow cytometry antibody |
APC anti-human CD9 | BioLegend | 312107 | Flow cytometry antibody |
BC CytoFLEX S | Beckman Coulter | BC CytoFLEX S equipped with 3 lasers, Blue, Red and Violet | |
Flow-Check Pro Fluorospheres | Beckman Coulter | A63493 | Fluorescent control beads for MoFLO Astrios EQ |
FlowJo software (version 10.8.1) | BD | version 10.8.1 | Analysis software |
IntraSure kit | BD Biosciences | 641776 | Fixation and permeabilization for intracellular staining |
Megamix-Plus FSC | BioCytex | 7802 | FSC polystyrene beads |
MoFLO Astrios EQ | Beckman Coulter | MoFLO Astrios EQ equipped with 4 lasers, Blue, Yellow - Green, Violet and Red | |
Mouse anti-FLOT1 antibody | BD Transduction Laboratories | 610820 | Western Blot antibody |
NanoSight NS300 | Malvern | NS300 | |
Rabbit anti-Calnexin antibody | Origene | TA336279 | Western Blot antibody |
Rabbit anti-CD9 and CD81 antibody (ExoAb antibody kit) | System Biosciences | EXOAB-KIT-1 | Western Blot antibodies |
Rabbit anti-TSG101 antibody | Merck | HPA006161 | Western Blot antibody |
Triton X-100 | Merck | 9036-19-5 | |
Ultra Rainbow Fluorescent Particles | Spherotech | URFP-30-2 | |
Ultracel 100 kDa MWCO | Merck | UFC910024 | |
VER01 - Verity Shells | Exometry | Organo silica beads for scatter calibration |
Request permission to reuse the text or figures of this JoVE article
Request PermissionExplore More Articles
This article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved